A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

The new Indian Council of Medical Research (ICMR) study shows that lung cancer incidence will be the highest in the ...

Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and ...

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients ...

Chinese pharma Hansoh Pharma (HKEX: 3692) has secured approval from China’s National Medical Products Administration for an ...

In return for the rights to YL201 outside China, MediLink will receive upfront and potential near-term milestone payments ...

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

Revolution Medicines shows RAS drug optimism with phase 3 catalysts, early-stage valuation, buyout chatter, and competition ...

HOUSTON, JANUARY 9, 2026 ― At The University of Texas MD Anderson Cancer Center , research breakthroughs are made possible through seamless ...

Noetik, an AI-native biotech company developing self-supervised machine learning and high-throughput spatial data to develop ...